WO2015073970A1 - Système de stabilité d'accès transseptal - Google Patents

Système de stabilité d'accès transseptal Download PDF

Info

Publication number
WO2015073970A1
WO2015073970A1 PCT/US2014/065954 US2014065954W WO2015073970A1 WO 2015073970 A1 WO2015073970 A1 WO 2015073970A1 US 2014065954 W US2014065954 W US 2014065954W WO 2015073970 A1 WO2015073970 A1 WO 2015073970A1
Authority
WO
WIPO (PCT)
Prior art keywords
venous sheath
stability system
transseptal
venous
sheath
Prior art date
Application number
PCT/US2014/065954
Other languages
English (en)
Inventor
Alan Cheng
George Coles
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Priority to US15/035,997 priority Critical patent/US20160270837A1/en
Publication of WO2015073970A1 publication Critical patent/WO2015073970A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34—Trocars; Puncturing needles
    • A61B17/3478—Endoscopic needles, e.g. for infusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238—Type of minimally invasive operation
    • A61B2017/00243—Type of minimally invasive operation cardiac
    • A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/30—Surgical pincettes without pivotal connections
    • A61B2017/306—Surgical pincettes without pivotal connections holding by means of suction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34—Trocars; Puncturing needles
    • A61B2017/348—Means for supporting the trocar against the body or retaining the trocar inside the body
    • A61B2017/3482—Means for supporting the trocar against the body or retaining the trocar inside the body inside
    • A61B2017/3484—Anchoring means, e.g. spreading-out umbrella-like structure
    • A61B2017/3488—Fixation to inner organ or inner body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A61B2018/0212—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument inserted into a body lumen, e.g. catheter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A61B2018/0231—Characteristics of handpieces or probes
    • A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M29/00—Dilators with or without means for introducing media, e.g. remedies

Definitions

  • the presently disclosed subject matter relates generally to transseptal access devices and more particularly to a transseptal access stability system (TASS) for reducing complications that may arise when performing transseptal punctures.
  • TASS transseptal access stability system
  • the left atrium of the heart is a challenging cardiac chamber to access
  • Puncturing the interatrial septum a procedure known as a transseptal puncture, permits a direct route from the right atrium to the left atrium.
  • Transseptal puncture procedures often involve the use of a venous sheath housing a needle capable of puncturing the interatrial septum through the fossa ovale and are critical for many invasive procedures performed in a cardiac catheterization laboratory.
  • Transseptal puncture procedures come with a significant risk of complications, many of which can be serious and life-threatening. While the incidence of complications has been reduced through advancements in sheath and real-time imaging technology, certain anatomic variations can increase the risk of serious complications. In particular, patients with atrial septal aneurysms remain at a particularly high risk of cardiac perforation that may require emergent cardiac surgery or even result in death. Current tools aimed to improve the safety profile of transseptal puncture procedures have limited efficacy.
  • the presently disclosed subject matter provides a transseptal access stability system (TASS) comprising a cardiac catheter, wherein the cardiac catheter comprises: a venous sheath comprising an orifice defined by a rim at a distal end thereof, wherein the rim is configured to secure a fossa ovale thereto, and wherein the venous sheath is fluidly coupled to at least one of a vacuum source and a cryoenergy source at a proximal end thereof; and a hollow dilator having a transseptal needle operationally positioned therein, wherein the dilator and needle are axially positioned through the venous sheath and wherein the dilator and the needle each have a distal end configured to protrude from the orifice at the distal end of the venous sheath and are adapted to be advanced and retracted to puncture a interatrial septum through the fossa ovale.
  • TASS transseptal access stability system
  • the venous sheath is curved at the distal end by an angle a, which in particular aspects can have a range from about 0 degrees to about 160 degrees.
  • angle a is fixed, whereas in other aspects, angle a is adjustable, for example, by a steering mechanism.
  • the venous sheath comprises a plurality of channels, wherein the plurality of channels is fluidly coupled to at least one of a vacuum source and a cryoenergy source at a proximal end thereof.
  • the presently disclosed subject matter provides a method for performing a transseptal puncture on a subject in need of treatment thereof, the method comprising: (a) providing a transseptal access stability system (TASS) as disclosed herein and a J- wire; (b) accessing the femoral venous of the subject and inserting a J- wire into the vein thereof; (c) advancing the venous sheath with the assembled dilator of the TASS over the J-wire and into the vein; (d) once positioned in the heart of the subject, removing the J-wire and leaving the venous sheath and the dilator in place; (e) inserting the needle into the dilator; (f) positioning the venous sheath/dilator/needle assembly against the septum of the fossa ovale; (g) advancing the venous sheath over the dilator/needle until the venous sheath is in direct contact with the septal tissue;
  • kits comprising: (a) a transseptal access stability system of claim 1; and (b) a J-wire.
  • the kit comprises instructions for use of the kit for performing a transseptal puncture on a subject in need of treatment thereof.
  • FIG. 1 illustrates a schematic diagram of an embodiment of the presently disclosed transseptal access system (TASS);
  • FIG. 2 illustrates a side view of another embodiment of the presently disclosed
  • TASS illustrating a plurality of channels comprising the venous sheath, which are in fluid communication with a plurality of pores configured to secure the fossa ovale thereto;
  • FIG. 3 illustrates a plan view of the porous end cap of the TASS shown in FIG. 2;
  • FIG. 4A and FIG. 4B illustrate perspective views of another embodiment of the presently disclosed TASS comprising the cardiac catheter with a plurality of channels therein, wherein each channel has its own independently controlled vacuum or cryoenergy source;
  • FIG. 4C is a plan view and a side view of an embodiment of the TASS shown in FIGS. 4A and 4B including an end cap that is configured to allow a continuous flow of cryogen in and out of the cap;
  • FIG. 5 illustrates a flow diagram of an example of a method of performing a transseptal puncture using the presently disclosed TASS
  • FIG. 6 shows another configuration of the TASS shown in FIG. 1 in a
  • FIG. 7 shows a configuration of the TASS shown in FIG. 6 in an assembled state.
  • the term "fossa ovale” refers to a depression in the right atrium of the heart and is the remnant of a thin fibrous sheet that covers the foramen ovale during fetal development. An aneurysm can occur if the foramen ovale does not close properly. When an aneurysm occurs in the fossa ovale, an enlarged pouch is formed. This pouch can protrude into the right atrium or the left atrium. An aneurysm can occur even if the foramen ovale seals properly.
  • the presently disclosed transseptal access stability system includes a venous sheath that is designed to improve the safety profile of transseptal access in patients who have anatomical variants that may not be amenable to traditional approaches. More particularly, the venous sheath is designed for reducing the likelihood of atrial septal aneurysms when performing transseptal punctures.
  • the presently disclosed TASS can be used in any transseptal procedure and is not limited for use in patients with an atrial septal aneurysm. Further, any transseptal sheath currently known in the art can be retrofitted with the presently disclosed TASS.
  • the presently disclosed TASS is disposable and intended for a single use.
  • the TASS uses suction force for securing the fossa ovale against the rim of the orifice of the venous sheath.
  • the TASS uses cryo-based energy for securing the fossa ovale against the rim of the orifice of the venous sheath. Once the venous sheath is secured against the fossa ovale, the venous sheath can be retracted along with the fossa ovale to move it away from the left atrial free wall region. Puncturing of the fossa ovale can then be performed safely with minimal concern for perforating through to the free wall of the left atrium.
  • FIG. 1 is a schematic diagram of an embodiment of a TASS 100 for reducing the likelihood of atrial septal aneurysms when performing transseptal punctures.
  • the presently disclosed TASS 100 includes a cardiac catheter 110 that is supplied by either a vacuum source 150 or a cryoenergy source 160.
  • the cardiac catheter 110 includes a hollow venous sheath 115, which is, for example, a 9.5Fr sheath, although other diameter sheaths could be suitable for use with the presently disclosed TASS.
  • Venous sheath 115 in some embodiments, as illustrated in FIG. 2 herein below, can include a plurality of channels originating at the proximal end thereof, which are fluidly coupled to and can be supplied by either a vacuum source 150 or a cryoenergy source 160.
  • a steering mechanism 120 and a hemostatic valve 125 are coupled to the proximal end of the cardiac catheter 110.
  • Catheter steering mechanisms known in the art can be adapted to be suitable for use with the presently disclosed TASS.
  • a dilator 130 and a needle 135 are fed through the hollow venous sheath 115, the steering mechanism 120, and the hemostatic valve 125 as shown in FIG. 1 such that they are positioned axially within the hollow venous sheath 115 (see insert A-A).
  • Needles known in the art can be adapted to be suitable for use with the presently disclosed TASS.
  • Needle 135 optionally is provided with the presently disclosed TASS or, in other embodiments, needle 135 can be supplied separately.
  • the distal end of the venous sheath 115 has an orifice 140 through which the distal ends of the dilator 130 and the needle 135 can protrude.
  • Orifice 140 is defined by rim 140a.
  • rim 140a can comprise a porous end cap coupled thereto, which includes a plurality of pores in fluid
  • the venous sheath 115, the dilator 130, and the needle 135 can be advanced, retracted, and, in some embodiments, steered independently and in a controlled fashion.
  • Detail A in FIG. 1 shows an expanded view of the orifice 140 and rim 140a of the venous sheath 115, including an expanded view of the dilator 130 and needle 135.
  • Detail A also shows that the distal end of the venous sheath 115 can be set at an angle a with respect to a longitudinal axis AX along the length of the venous sheath 115.
  • the angle a can range from about 0 degrees to about 160 degrees, including 0, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, and 160 degrees, ⁇ 5 degrees and any whole or fractional integer in between.
  • the angle a is adjustable through a mechanism within the venous sheath 115 so that the operator can custom tailor the degree of angulation.
  • the steering mechanism 120 e.g., a dial
  • the steering mechanism 120 is used to change the steerability and angulation of the venous sheath 115.
  • the vacuum source 150 is fluidly coupled to the venous sheath 115 via a side port 145.
  • a regulator 155 may be associated with the vacuum source 150 for controlling uniform vacuum pressure within the venous sheath 115. More particularly, in this embodiment, a vacuum (i.e., a pressure significantly below atmospheric pressure) exists in the space between the venous sheath 115 and the dilator 130. When in use, suction force is used to secure the fossa ovale against the rim 140a of the orifice 140 of the venous sheath 115.
  • cryoenergy source 160 is fluidly coupled to the venous sheath 115 via the side port 145.
  • a regulator 165 may be associated with the cryoenergy source 160 for controlling the flow of coolant and thereby controlling the temperature at the orifice 140 of the venous sheath 115.
  • the rim 140a of the orifice 140 of the venous sheath 115 is cooled to cryogenic temperatures.
  • cryoenergy is used to secure the fossa ovale against the rim 140a of the orifice 140 of the venous sheath 115, i.e., the fossa ovale adheres to the rim 140a of the orifice 140.
  • FIG. 2 is a side view of a TASS 200, which is another embodiment of the presently disclosed TASS. More particularly, FIG. 2 further defines the presently disclosed venous sheath, which stabilizes the fossa ovale, secures the interatrial septum, and allows for a safe needle puncture.
  • the presently disclosed TASS 200 includes a cardiac catheter 210.
  • the cardiac catheter 210 includes a venous sheath 215.
  • Venous sheath 215 includes a plurality of channels 220 originating at the proximal end thereof, which can be supplied by either a vacuum source or a cryoenergy source (not shown), such as the vacuum source 150 or the cryoenergy source 160 shown in FIG. 1.
  • Cardiac catheter 210 further includes catheter insertion cavity (or lumen) 230 for receiving a dilator 232 and a needle 235.
  • FIG. 2 also shows a cross-sectional view of the cardiac catheter 210 taken along line A- A of the side view, which shows more details of the channels 220 and the catheter insertion cavity 230 of the cardiac catheter 210.
  • the venous sheath 215 of cardiac catheter 210 includes a porous end cap 240a, which is coupled to orifice 240 at the distal end thereof.
  • Porous end cap 240a includes a plurality of pores 250. More details of the porous end cap 240a are shown with reference to FIG. 3.
  • FIG. 3 is a plan view of the porous end cap 240a of the TASS 200 shown in FIG. 2. Also shown in FIG. 3 are cross-sectional views of examples of pores 250, taken along line B-B of the plan view.
  • the plurality of pores 250 can have any shape and geometry configured to improve the suction force for securing the fossa ovale thereto.
  • Representative geometries of the plurality of pores 250 include, but are not limited to, a straight-walled hole 250a, an idealized taper 250b, a trumpet geometry 250c, a wine glass geometry 250d, and a champagne flute geometry 250e.
  • FIG. 4A is a perspective view of an TASS 400, which is yet another embodiment of the presently disclosed TASS.
  • the cardiac catheter of the TASS 400 comprises a plurality of independently controlled channels.
  • the TASS 400 comprises a cardiac catheter 410.
  • the cardiac catheter 410 includes a venous sheath 415.
  • the venous sheath 415 of the cardiac catheter 410 further includes a catheter insertion cavity (or lumen) 420 for receiving a dilator (not shown) and a needle (not shown).
  • a catheter insertion cavity (or lumen) 420 for receiving a dilator (not shown) and a needle (not shown).
  • Integrated into the walls of the venous sheath 415 is a plurality of channels 425 originating at the proximal end thereof.
  • the venous sheath 415 comprises eight channels 425.
  • each of the eight channels 425 has a flexible fluid line 430 extending from the proximal end of the venous sheath 415.
  • each of the flexible fluid lines 430 has a coupler 435.
  • Each of the eight channels 425 is supplied by its own vacuum source 150 or cryoenergy source 160.
  • the eight channels 425 are supplied by eight vacuum sources 150, respectively, or by eight cryoenergy sources 160, respectively. Accordingly, each of the eight channels 425 can be independently controlled.
  • Venous sheath 415 can comprise a plurality of channels 425, including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more channels 425.
  • FIG. 4B is an expanded view of the distal end of the venous sheath 415 of the cardiac catheter 410.
  • the distal end of the venous sheath 415 can be set at a substantially fixed angle a with respect to a longitudinal axis AX along the length of the venous sheath 415.
  • the angle a can range from about 0 degrees to about 160 degrees. Further, the angle a is adjustable through a mechanism within the venous sheath 415 so that the operator can custom tailor the degree of angulation.
  • Cap 440 can fit over the distal end of venous sheath 415 and has channels 445 that substantially align with channels 425 of venous sheath 415.
  • Cap 440 also has a channel 450 that is common to all of channels 445 which allows a continuous flow of cryogen in and out of cap 440.
  • a gas e.g., nitrous oxide, can flow through cap 440, and when it expands upon exiting one or more of channels 425, causes cap 440 to cool and adhere to the fossa ovale when contacted with the tissue thereof.
  • the cryogen can be continuously supplied to cap 440 by cryoenergy source 160 one or more channels 425 and removed from cap 440 by vacuum applied to one or more channels 425 by vacuum source 150.
  • channel 420 also is available for supplying and/or removing the cryogen from cap 440.
  • TASS 400 is substantially a close-looped system.
  • the TASS 100, 200, or 400 can comprise non-steerable sheaths that have different degrees of angles preformed.
  • FIG. 5 is a flow diagram of an example of a method 500 of performing a transseptal puncture using the presently disclosed TASS 100, 200, or 400.
  • the method 500 may include, but is not limited to, the following steps.
  • the presently disclosed TASS 100, 200, or 400 is provided.
  • FIG. 6 shows an example of TASS 100 that is provided in a disassembled state.
  • FIG. 6 shows separately the cardiac catheter 110, the dilator 130 (e.g., a plastic dilator), and a J-wire 170 (e.g., a 0.035 inch J-wire).
  • J-wire 170 can be provided with TASS 100 or, in some embodiments, J-wire 170 is provided separately.
  • the cardiac catheter 110 has the vacuum source 150 (e.g., a syringe) coupled thereto via the side port 145.
  • TASS 100 also includes a pressure gauge 152 and a one-way valve (not shown).
  • FIG. 7 shows the dilator 130 inserted into a catheter insertion cavity (or lumen) 117 of the venous sheath 115 and the J-wire 170 inserted in a lumen 132 of the dilator 130.
  • the femoral venous is accessed in the standard clinical manner and the J-wire 170 is inserted into the vein.
  • the venous sheath 115 with the assembled dilator 130 is advanced over the J-wire 170 and into the vein.
  • the J-wire 170 is removed leaving the venous sheath 115 and the dilator 130 in place.
  • a needle e.g., the needle 135
  • the venous sheath 115/dilator 130/needle 135 assembly is positioned against the septum of the fossa ovale.
  • the venous sheath 115 is advanced over the dilator 130/needle 135 assembly until the venous sheath 115 is in direct contact with the septal tissue.
  • suction force is applied to the venous sheath 115.
  • the vacuum source 150 e.g., a syringe
  • the transseptal puncture is performed using the needle 135.
  • the suction force is released and the venous sheath 115 and the dilator 130 are advanced across the punctured septum.
  • the presently disclosed subject matter provides a kit comprising: (a) a transseptal access stability system of disclosed herein; and a J-wire.
  • the kit includes instructions for use of the kit for performing a transseptal puncture on a subject in need of treatment thereof, for example, steps of method 500 disclosed immediately hereinabove.
  • the presently disclosed TASS is designed to significantly improve the safety profile of transseptal access in patients that have anatomical variants that may not be amenable to traditional approaches.
  • the venous sheath is designed for reducing the likelihood of atrial septal aneurysms when performing transseptal punctures.
  • the TASS uses suction force from the vacuum source for securing the fossa ovale.
  • the TASS uses cryo-based energy for securing the fossa ovale. Once the venous sheath is secured against the fossa ovale, the venous sheath can be retracted along with the fossa ovale to move it away from the left atrial free wall region. Puncturing of the fossa ovale can then be performed safely with minimal concern for perforating through to the free wall of the left atrium.
  • embodiments is desirably a human subject, although it is to be understood that the methods described herein are effective with respect to all vertebrate species, which are intended to be included in the term "subject.”
  • a "subject" can include a human subject for medical purposes, such as for the treatment of an existing condition or disease or the prophylactic treatment for preventing the onset of a condition or disease, or an animal subject for medical, veterinary purposes, or developmental purposes.
  • Suitable animal subjects include mammals including, but not limited to, primates, e.g., humans, monkeys, apes, and the like; bovines, e.g., cattle, oxen, and the like; ovines, e.g., sheep and the like; caprines, e.g., goats and the like; porcines, e.g., pigs, hogs, and the like; equines, e.g., horses, donkeys, zebras, and the like; felines, including wild and domestic cats; canines, including dogs; lagomorphs, including rabbits, hares, and the like; and rodents, including mice, rats, and the like.
  • an animal may be a transgenic animal.
  • the subject is a human including, but not limited to, fetal, neonatal, infant, juvenile, and adult subjects.
  • a "subject” can include a patient afflicted with or suspected of being afflicted with a condition or disease.
  • the terms “subject” and “patient” are used interchangeably herein.
  • the terms “a,” “an,” and “the” refer to "one or more" when used in this application, including the claims.
  • reference to “a subject” includes a plurality of subjects, unless the context clearly is to the contrary (e.g., a plurality of subjects), and so forth.
  • the term "about,” when referring to a value can be meant to encompass variations of, in some embodiments, ⁇ 100% in some embodiments ⁇ 50%, in some embodiments ⁇ 20%>, in some embodiments ⁇ 10%, in some embodiments ⁇ 5%, in some embodiments ⁇ 1%, in some embodiments ⁇ 0.5%, and in some embodiments ⁇ 0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.

Abstract

L'invention concerne un système de stabilité d'accès transseptal (TASS) et son procédé d'utilisation. Le TASS comprend une gaine veineuse pour réduire la probabilité de complications qui peuvent survenir lors de la réalisation de ponctions transseptales. Le TASS utilise une force d'aspiration ou une énergie cryogénique pour fixer la fosse ovale contre le bord de l'orifice de la gaine veineuse. L'invention concerne également un procédé pour réaliser une ponction transseptale à l'aide du présent TASS.
PCT/US2014/065954 2013-06-21 2014-11-17 Système de stabilité d'accès transseptal WO2015073970A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/035,997 US20160270837A1 (en) 2013-06-21 2014-11-17 Atrial septal aneurysm transseptal access system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904699P 2013-11-15 2013-11-15
US61/904,699 2013-11-15

Publications (1)

Publication Number Publication Date
WO2015073970A1 true WO2015073970A1 (fr) 2015-05-21

Family

ID=53058138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/065954 WO2015073970A1 (fr) 2013-06-21 2014-11-17 Système de stabilité d'accès transseptal

Country Status (1)

Country Link
WO (1) WO2015073970A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195432A1 (fr) * 2017-04-20 2018-10-25 Medtronic, Inc. Stabilisation de dispositif d'administration transseptale

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234437A1 (en) * 1999-07-14 2005-10-20 Cardiofocus, Inc. Deflectable sheath catheters with out-of-plane bent tip
US20100185141A1 (en) * 2007-04-27 2010-07-22 CVDeices, LLC (a California limited liability company) Devices and methods for securing a catheter within a heart
US20110270239A1 (en) * 2010-04-29 2011-11-03 Werneth Randell L Transseptal crossing device
US8052677B2 (en) * 2003-02-13 2011-11-08 Coaptus Medical Corporation Transseptal left atrial access and septal closure
US20130123620A1 (en) * 2011-11-16 2013-05-16 Cook Medical Technologies Llc Tip deflecting puncture needle

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234437A1 (en) * 1999-07-14 2005-10-20 Cardiofocus, Inc. Deflectable sheath catheters with out-of-plane bent tip
US8052677B2 (en) * 2003-02-13 2011-11-08 Coaptus Medical Corporation Transseptal left atrial access and septal closure
US20100185141A1 (en) * 2007-04-27 2010-07-22 CVDeices, LLC (a California limited liability company) Devices and methods for securing a catheter within a heart
US20110270239A1 (en) * 2010-04-29 2011-11-03 Werneth Randell L Transseptal crossing device
US20130123620A1 (en) * 2011-11-16 2013-05-16 Cook Medical Technologies Llc Tip deflecting puncture needle

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195432A1 (fr) * 2017-04-20 2018-10-25 Medtronic, Inc. Stabilisation de dispositif d'administration transseptale
EP4005500A1 (fr) * 2017-04-20 2022-06-01 Medtronic, Inc. Stabilisation de dispositif d'administration transseptale
US11832829B2 (en) 2017-04-20 2023-12-05 Medtronic, Inc. Stabilization of a transseptal delivery device

Similar Documents

Publication Publication Date Title
US20160270837A1 (en) Atrial septal aneurysm transseptal access system
US20210290213A1 (en) Vessel access and closure assist system and method
US6500157B2 (en) Intravenous infusion needle with soft body
JP6043301B2 (ja) 血管用針システム
US20150182730A1 (en) Microaccess kit comprising a tapered needle
JP2018518221A5 (fr)
JP5105939B2 (ja) 医療用挿入ガイド器具
US9248264B2 (en) Dilator, introducer assembly, and medical tool
JP2013013592A (ja) 脳室穿刺用ダイレータ装置
EP2662039A2 (fr) Appareil à aiguille transseptale
EP2560556B1 (fr) Dispositif hémostatique
CA2818600A1 (fr) Canule a autodilatation
WO2015073970A1 (fr) Système de stabilité d'accès transseptal
US9687269B2 (en) Hemodialysis double lumen needle angio catheter
US20150011978A1 (en) Introducer sheath
CN106377301B (zh) 血管穿刺器
CN205054307U (zh) 微创头皮牵开器
US9642604B2 (en) Hemostatic system and its methods of use
US9333295B2 (en) Thermotherapy needling instrument with tissue injection
CN106344145B (zh) 带导丝引导装置的软管冷冻探针及使用方法
JP5877944B2 (ja) イントロデューサー組立体
CN217285986U (zh) 一种胸腔镜一次性手汗症穿刺鞘管
CN109431619A (zh) 手术中的定位标记装置
US11622790B2 (en) Obturators for surgical access assemblies and methods of assembly thereof
JP2001238947A (ja) 穿刺具および穿刺具セット

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14862447

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15035997

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14862447

Country of ref document: EP

Kind code of ref document: A1